Publications

sex positions to get pregnant

Tags:

abortion brooklyn

abortion center

Abortion Clinic

abortion clinic brooklyn

Complete obstetric care

surgical abortion nyc

vaginoplastabortion clinic nyc

Cervicitis is characterized by inflammation of the cervix. The cervix is the lower end or the lower opening of the uterus. Anything from an infection to an injury involving the cervical tissue may cause cervicitis (Readalso: Cervical Polyps). This kind of disease is a common gynecological condition in women and tends to recur in 8-25% of the women who have had it before. It also requires prompt treatment as the inflammation is likely to spread from the cervix to the rest of the female reproductive tract.

What Causes Cervicitis?
This disease may result from a number of factors. Following is a list of the most common causes of this condition.

Hormonal imbalances that lead to lower estrogen levels and higher progesterone levels in the blood stream may harm the cervical tissue to result in inflammatory changes and cervicitis.
Entry of harmful bacteria into the vagina that results in a higher number of harmful bacteria as compared to the healthy vaginal flora may result in bacterial vaginosis and cervicitis.
Sexually transmitted diseases like Gonorrhea, genital herpes, Chlamydia, and trichomonas may also result in this condition. Generally, unprotected sex or sex with multiple partners increases a woman’s risk of cervicitis from STDs.
Allergic reaction of the cervical tissue to douches, spermicides, or latex condoms may also lead to this disease. Similarly, injury from tampons, diaphragms or other intra-uterine birth control devices, and pessaries may also result in the same.

Brooklyn Abortion Clinic
14 DeKalb Avenue 4 floor,
Brooklyn, NY 11201
(718) 369–1900

Web Address: https://www.brooklynabortionclinic.nyc/

Our location on the map: https://goo.gl/maps/PiZocruzmE7w1BLx6
https://plus.codes/87G8M2Q9+V4 Brooklyn

Working Hours:
Mon — Sun: 7:00 am — 10:00 pm

Payment: cash, check, credit cards.

view in full page

9 months, 2 weeks ago

13783
0
Facebook

Twitter

Google+

LinkedIn

Report

Endometriosis treatment

Brooklyn Abortion Clinic

Directory:

sex positions to get pregnant

Tags:

abortion brooklyn

abortion center

Abortion Clinic

abortion clinic brooklyn

Complete obstetric care

surgical abortion nyc

vaginoplastabortion clinic nyc

Many women diagnosed with endometriosis have very painful sexual intercourse. Some of them even give up from having sexual intercourse with their partner at all. This all leads to serious relationship problems, a lack of self – esteem, and even personality problems.

Painful Sexual Intercourse & Relationships
But how can you enjoy having sex while it hurts? It is normal for women who experience sex not to want it and even be unable to enjoy it. Can this pain be treated? Are there any solutions which will help make sex satisfying again? These are some of the questions that every women suffering from endometriosis and having painful sexual intercourse will try to get an answer.

According to many researches among women diagnosed with endometriosis, it has been estimated that more than half of them have painful sexual intercourse. Women, who have this kind of problems, often tend to be embarrassed and find it very difficult to talk to their partners about it. This makes it all even more frustrating for them. But there is and should be not just a women’s problem. It should be a problem of both of the partners, a problem in couple. Only together with the partner, you as a women can manage to get over it and find the best solution when it comes to sex for both of you.

Some women find it also very difficult to talk to their problem with the gynecologist. But as mentioned before there is nothing to be embarrassed off.

Brooklyn Abortion Clinic
14 DeKalb Avenue 4 floor,
Brooklyn, NY 11201
(718) 369–1900

Web Address: https://www.brooklynabortionclinic.nyc/
Our location on the map: https://goo.gl/maps/PiZocruzmE7w1BLx6
https://plus.codes/87G8M2Q9+V4 Brooklyn

Working Hours:
Mon — Sun: 7:00 am — 10:00 pm

Payment: cash, check, credit cards.

view in full page

9 months, 3 weeks ago

15942
0
Facebook

Twitter

Google+

LinkedIn

Report

Neurosurgery 2040

HealthPad

Directory:

Neurosurgery

Tags:

Over the past two decades, neurosurgery has been transformed by technological advancements, interdisciplinary collaboration, and a deeper understanding of the brain
Breakthroughs like functional magnetic resonance imaging and minimally invasive surgery have enhanced diagnostics and treatments, steering the field away from its conventional practices
By 2040, such changes will continue and accelerate as neurosurgery embraces augmented reality interfaces, robotics, and artificial intelligence, facilitating personalised interventions based on individual genetic profiles
The future of neurosurgery will not only showcase technological excellence but also a heightened commitment to ethical principles prioritising patient welfare and societal wellbeing

Neurosurgery 2040

Over the past two decades, neurosurgery has undergone a transformation, marked by increased precision, less invasive procedures, and swifter recovery, all driven by technological advances, interdisciplinary collaboration, and an enhanced comprehension of the brain. Progress ranges from neuroimaging technologies to refined surgical techniques. This Commentary briefly describes the milestones and ethical considerations of neurosurgery up to ~2040.

Since 2000, the convergence of technologies such as functional magnetic resonance imaging (fMRI) and minimally invasive surgery has improved diagnostic approaches and treatment methodologies. Departing from conventional norms, the advent of personalised medicine and the rise of neurostimulation hold the promise of advancing our comprehension and treatment of neurological disorders.

Looking forward to ~2040, we foresee these trends intensifying, with operating rooms (OR) equipped with state-of-the-art technologies like augmented reality interfaces, robotics, and artificial intelligence (AI), synergising with human expertise. Envisage progress in targeted medicine to also continue and further disrupt neurosurgical treatments by customising interventions according to individuals' distinctive genetic profiles and incorporating developments in gene therapies. As these technologies augment cognitive capabilities, addressing ethical concerns to increase in importance will become more relevant. Prioritising moral considerations will be essential to ensure responsible and compassionate utilisation of these tools.

Furthermore, the upcoming collaboration spanning various fields is positioned to speed up, playing a crucial role in driving neurosurgery to unprecedented levels. This cooperative endeavour is expected to break down traditional barriers and enhance our understanding of the complexities of the brain. Looking forward to 2040, an intensified sense of purpose among healthcare providers is predicted, highlighted by heightened global awareness and strategic initiatives aimed at reducing healthcare disparities by broadening access to neurosurgical expertise worldwide. Underscoring the increasing significance of robust ethical guidelines and ongoing dialogues, we highlight the importance of steering the path of neurosurgery beyond technical innovations. Contemplate a growing focus on ethical principles that prioritise patient welfare and societal wellbeing, indicating that the future of neurosurgery will be characterised by a blend of technological expertise and a more pronounced commitment to human values and purpose.

In this Commentary

This Commentary has two parts. Its overall aim is to nudge neurosurgeons and providers to reflect on their current modus operandi and strategically prepare for the future. Part 1, Neurosurgery since 2000, briefly describes technological developments and interdisciplinary collaboration, which have improved diagnostics, treatments, and our understanding of the complexities of the brain. Part 2, Neurosurgery 2040, anticipates integrated operating rooms where augmented reality, robotics, and AI merge with human expertise. This forward-looking approach stresses interdisciplinary collaboration and a purpose-driven mindset to enhance access to efficacious therapies.

Part 1
Neurosurgery since 2000

Over the past two decades, neurosurgery has evolved at a pace unparalleled in its history. From advancements that have improved diagnosis to the refinement of surgical techniques, the field, since the turn of the millennium, has been a testament to the determined pursuit of knowledge and the inventive spirit within the medical community. We briefly describe aspects of this transformative journey, shedding light on a few key milestones, ethical considerations, and the promising trajectory that lies ahead.

Technologies such as fMRI, diffusion tensor imaging (DTI), and positron emission tomography (PET) have become essential tools to improve diagnostics. Concurrently, minimally invasive surgical approaches, guided by real-time imaging, have not only reduced invasiveness but have also improved patient outcomes. The collaboration between advanced neuroimaging and refined surgical methods marks a shift in neurological care, by facilitating more precise and effective interventions. Indeed, a hallmark of neurosurgery's evolution since 2000 has been the increased use of precision medicine. Departing from the traditional one-size-fits-all approach, the field has shifted towards tailoring treatments based on individual genetic, molecular, and physiological characteristics. Genetic profiling, biomarker identification, and targeted therapies have emerged as effective tools to enhance diagnostic accuracy and pave the way for the expansion of personalised therapies. This departure from conventional approaches suggests a future where neurosurgical treatments are as unique as the individuals they seek to assist.

Empowered by technological progress, surgeons can now probe the brain with newfound precision and safety. Minimally invasive approaches, including endoscopic and stereotactic procedures, have minimised trauma, accelerated recovery times, and expanded the scope of what is surgically achievable. Neuron-navigation systems and robotic-assisted surgeries have further enhanced neurosurgical practice, redefined possibilities, and improved outcomes. The rise of minimally invasive procedures has not only reshaped neurosurgery but has also facilitated patient-friendly approaches over traditional open surgeries. Techniques such as endoscopic and laparoscopic procedures significantly reduce physical tolls on patients, improve recovery times, and minimise complications. Equipped with specialised tools and advanced imaging, neurosurgeons can navigate through the brain's structures with minimal disruption, and not only provide medical advantages but also cosmetic benefits and faster postoperative rehabilitation.

Since 2000, neurostimulation has introduced novel therapeutics for various neurological disorders. Technologies such as deep brain stimulation (DBS) and spinal cord stimulation (SCS) have brought relief to conditions such as Parkinson's disease and chronic pain. The integration of adaptive neurostimulation guided by real-time feedback, represents a shift towards personalised and adaptive treatments, offering hope for an improved quality of life.

You might also like:

Brain disorders and the changing nature of neurosurgery

The burgeoning field of neurogenetics investigates the interplay between genes and complex neural networks. Personalised therapies, which have evolved from unravelling unique genetic signatures, hold promise for conditions such as Alzheimer's, Parkinson’s, and epilepsy. Neurogenetics not only carries the potential for targeted interventions but also provides insights into the individuality of our minds, suggesting a new era where the enigmas of cognition are elucidated.

Interdisciplinary approaches drive breakthroughs in neurosurgery that go beyond traditional boundaries. The fusion of neuroscience with engineering, computer science, and genetics enhances our understanding of the brain, leading to creative solutions. Whether neurosurgeons collaborate with engineers or data scientists, these partnerships redefine possibilities within the field, pointing towards a future where the complexities of the brain are unravelled through a range of capabilities. Translational research in neurological disorders provides additional hope by linking theoretical breakthroughs to tangible results. The combined efforts of researchers, clinicians, and pharmaceutical experts expedite the development of innovative therapies, bringing optimism to those affected by neurosurgical disorders.

Neurosurgical progress brings hope, yet finding a balance between technological development and ethical challenges is essential. While innovations hold promise, the ethical considerations associated with interventions related to the brain, including matters such as informed consent and privacy, become increasingly complex. Thus, it is crucial to reconcile the progress in neurosurgery with an awareness of ethical responsibilities, ensuring the utmost respect for the human mind.

Part 2
Neurosurgery 2040

Neurosurgery 2040 envisions a future shaped by ongoing developments since 2000, described in Part 1. Though predicting specifics is challenging, key trends are gaining momentum and set to rapidly redefine the field over the next two decades. The integration of AI and novel technologies, collaborative efforts across disciplines, a shift towards patient-focused precision care, improved accessibility to neurosurgical interventions, and a heightened focus on ethical considerations collectively signal the nature of forthcoming transformation. While these trends have been evolving since 2000, it is important to note the accelerated pace at which they are expected. This underscores the need for clinicians and providers to proactively prepare for imminent paradigm shifts. This section offers a partial glimpse into potential aspects of neurosurgery in 2040, emphasising the urgency for adaptation and innovation.

In January 2024, Neuralink, founded by Elon Musk in 2016, achieved a significant milestone by successfully implanting its inaugural device into a human patient. This marked progress towards realising Musk's visionary goal of helping individuals grappling with paralysis and diverse neurological conditions. Concurrently, Jaguar Gene Therapy secured FDA approval for its gene therapy designed to address genetic manifestations of autism spectrum disorder and Phelan-McDermid syndrome, instilling hope in thousands of individuals who have lacked effective treatment options.

While traumatic brain injury (TBI) continues to be a pervasive global health concern, affecting millions annually, (in the US ~2m cases each year), the resultant annual global burden on healthcare, patients, families, and society amounts to ~US$400bn. The current gold standard management of severe TBI involves an invasive procedure, which entails drilling a hole in the skull to insert a catheter for monitoring intracranial pressure (ICP). However, the evolution of neurosurgical techniques suggests that this invasive process will become obsolete by 2040. Emerging innovations are poised to replace it with a non-invasive method for monitoring ICP.

You might also like:

Healthcare 2040

Such breakthroughs provide a glimpse into the future landscape of neuro-trauma and neuro-disorders expected by 2040, highlighting the rapid pace of progress in the field. It seems plausible to posit that, as neurosurgery undergoes these, and other, changes, clinicians and healthcare providers will witness a paradigm shift, fostering an evolution in patient outcomes and reshaping neurological care.

Expect the continued development and increasing adoption of minimally invasive techniques, neuroimaging, nanotechnology, and targeted therapies. These advancements are poised to replace standard surgical approaches in neurosurgery, leading to a significant improvement in the overall patient experience and making interventions more accessible. The future of neurosurgery envisions the use of microscopic robotics for intricate procedures, steering away from invasive surgeries and embracing non-invasive alternatives. AI techniques are set to play a crucial role, serving as co-pilots by analysing real-time data. Additionally, genetic insights will inform tailored interventions in this collaborative environment, blurring interdisciplinary boundaries and signalling a departure from conventional approaches. The focal point of this shift is personalised care.

Within this evolving ecosystem, genetic profiling empowers neurosurgeons to design custom neural implants and gene therapies. This has the potential to significantly reduce the need for invasive procedures. These changes highlight the urgency for adaptation and innovation in the field, underscoring the importance of staying at the forefront of these technological and medical advancements.

By 2040, a confluence of neurogenetics, personalised neurosurgical therapies, and genetic engineering is anticipated to surpass conventional medical norms. Novel technologies will unravel the intricate interplay between genetics and neurological disorders, delivering custom-made solutions, significantly reducing risks, and optimising therapeutic outcomes. In the approaching years leading up to 2040, Western providers are positioned to align themselves with a defined 'purpose' and actively participate in initiatives aimed at enhancing access to high-quality healthcare. While these pursuits complement the traditional focus on maximising returns for investors, they are increasingly becoming an intrinsic part of the worldview and demands of Generation Z. The imperative for traditional providers to adopt a purpose-driven ethos and acknowledge their global responsibilities is important, and encouraged by a growing call for greater inclusivity. Foresee a surge in global awareness regarding healthcare disparities, prompting a commitment to leveraging technology for the advancement of worldwide healthcare accessibility. A socially responsible approach, incorporating ethical business practices and community engagement, is not only a moral imperative but is also foreseen to contribute significantly to the enduring sustainability of the MedTech industry.

As we approach 2040, Western neurosurgical providers will be expected to adopt a sharper 'ethical' focus, particularly in response to the escalating utilisation of neural implants and genetic therapies. While many MedTechs currently profess ethical awareness, the impending changes in neurosurgery underscore the necessity for a significant revaluation and augmentation of ethical strategies.

As neurosurgery advances with the further introduction of disruptive technologies and heightened cognitive capabilities, ethical considerations are projected to take centre stage. Deliberations on fairness, consent, and the definition of "normal" cognitive function converge with the emergence of neuroenhancement techniques and the integration of brain-computer interfaces. Ethical frameworks will be indispensable to mitigate and prevent biases in AI algorithms, address privacy concerns, and ensure the judicious utilisation of genetic information.

Effectively navigating these moral complexities demands not only technical innovation but also a robust moral compass to align enhanced cognition with human values. The evolving interplay between ethical considerations and technical progress underscores the imperative for ongoing dialogues among neuroscientists, ethicists, and policymakers. The overall objective is to shape the future of neurosurgery not solely through technological advancements but by integrating ethical principles that prioritise patient welfare and contribute to societal wellbeing.

Takeaways

We have described the transformative journey that neurosurgery has undertaken over the past two decades and provided a glimpse into its future. From the integration of breakthrough neuroimaging technologies to the emergence of precision medicine, neurosurgery has evolved, promising enhanced diagnostics and personalised therapies.

As we cast our gaze forward to 2040, a future unfolds where operating rooms are integrated with augmented reality interfaces, robotics, and AI, working in tandem with human expertise. Precision medicine takes centre stage, tailoring neurosurgical interventions to individual genetic profiles. However, the progress is not without its ethical challenges. The heightened cognitive abilities brought about by innovative technologies demand an appreciation for morality to ensure responsible and compassionate use. We stress the increasing significance of interdisciplinary collaboration, transcending traditional boundaries to foster a deeper understanding of the brain, and suggest a future where medical technology providers embrace a heightened sense of purpose, addressing global healthcare disparities by expanding access to neurosurgical expertise worldwide. Emphasising the critical role of robust ethical frameworks and ongoing dialogues, the Commentary suggests the future of neurosurgery should not only be defined by technical prowess but must also prioritise ethical principles that safeguard patient welfare and societal wellbeing.

Overall, the Commentary is a nudge for neurosurgery clinicians and providers to reflect on their current positions and prepare for a different future as the field is developing fast. Our two-part exploration, spanning the past two decades and projecting into Neurosurgery 2040, encourages a forward-looking approach marked by interdisciplinary collaboration and a purpose-driven mindset. The vision presented suggests that the future of neurosurgery will be characterised by a blend of technological expertise and a commitment to human values, ensuring that the field continues to develop ethically and deliver impactful, accessible, and compassionate care to individuals worldwide.

view in full page

9 months, 3 weeks ago

9351
0
Facebook

Twitter

Google+

LinkedIn

Report

Cervical biopsy procedure

Brooklyn GYN Place

Directory:

Tags:

endometriosis treatment

Cervical Biopsy Brooklyn NYCThe cervix is the lower part of the uterus that forms a canal that opens into the vagina and leads to outside the body. The tissue that’s removed is then closely examined under a microscope.

A cervical biopsy is normally performed during a colposcopy procedure or Pap Smear biopsy procedure.

Cervical Biopsy What Is a Cervical Biopsy?
A cervical biopsy is a procedure that is performed to remove tissue from the cervix to test for abnormal cells or precancerous conditions.

Cervical Biopsy or Punch Biopsy
The amount of tissue your doctor removes is dependent on the type of GYN biopsy being done. A simple cervical biopsy procedure, also known as a punch biopsy, removes a small piece of tissue from the surface of the cervix, where as an endocervical biopsy (endocervical curettage) removes tissue from high in the cervical canal and requires scraping with a sharp instrument.

Cone Biopsy
Cone biopsy Brooklyn NYCAnother possible GYN biopsy is a cervix cone biopsy or conization where your doctor will use a laser or scalpel to remove a large cone shaped piece of tissue from the cervix.

Lastly, there is the Loop Electrosurgical Excision procedure (LEEP) that uses a thin, low-voltage electrified wire loop to cut out any abnormal tissue found. In addition to removing tissue for testing, some of these procedures can be used to completely remove areas of abnormal tissue and may also be used in the treatment of precancerous lesions.

If you’re undergoing a cervix biopsy procedure that requires a general anesthetic, you’ll need to stop eating at least eight hours before the procedure.

Brooklyn GYN Place
142 Joralemon Street, #4CF,
Brooklyn, NY 11201
(718) 624-0604

Web Address:
https://www.brooklyngynplace.com/

Our location on the map: https://goo.gl/maps/TdxdKLtq6PuS65ck9

Nearby Locations:
Downtown Brooklyn | Fort Greene | Boerum Hill | Cobble Hill | Columbia Street Waterfront District
11201| 11205 | 11217 | 11238 | 11231

Working Hours:
Monday - Friday: 9am - 5:30pm
Saturday: 9am - 11:30am
Sunday: Closed

Payment: cash, check, credit cards.

view in full page

9 months, 3 weeks ago

11122
0
Facebook

Twitter

Google+

LinkedIn

Report

Signs and symptoms of uterine fibroids

Brooklyn GYN Place

Directory:

Tags:

endometriosis specialist nyc

endometriosis treatment

hymen removal surgery

labiaplasty nyc

pelvic floor reconstruction

pelvic sonogram

pelvic ultrasound

septate hymen surgery

What Are Uterine Fibroids?
Uterine fibroids treatment Brooklyn, NYUterine fibroids develop in the womb and are muscular tumors. They are usually benign, and less than one in 1000 will become cancerous. Having fibroids does not increase your risk of developing another form of cancer in the uterus. Fibroids are usually round, and although they consist of the same smooth muscle as the wall of the uterus, they are much denser. Uterine fibroids may develop singly, or you might have multiple tumors. They can be very small or might grow to become grapefruit sized.

Who Gets Uterine Fibroids?
Uterine fibroids generally develop during the 30s, 40s, and through menopause but are most common amongst women in their 40s and early 50s. Genetics is another factor as if your mother or another close female relative had fibroids, your risk is approximately three times higher than average.
Overweight women are at higher risk, especially those who are very heavy. Your ethnicity also makes a difference, as African-American women are more at risk than white women. If you like to eat plenty of red meat and ham, you are more likely to get fibroids compared with a woman who eats lots of green vegetables, which seems to have a protective effect.

Brooklyn GYN Place
142 Joralemon Street, #4CF,
Brooklyn, NY 11201
(718) 624–0604

Web-address: https://www.brooklyngynplace.com/

Location on the map: https://goo.gl/maps/TdxdKLtq6PuS65ck9

Nearby Locations:
Downtown Brooklyn | Fort Greene | Boerum Hill | Cobble Hill | Columbia Street Waterfront District
11201| 11205 | 11217 | 11238 | 11231

Working Hours:
Monday — Friday: 9am — 5:30pm
Saturday: 9am — 11:30am
Sunday: Closed

Payment: cash, check, credit cards.

view in full page

10 months, 1 week ago

15069
0
Facebook

Twitter

Google+

LinkedIn

Report

Is MedTech Entering a New Era of Leadership and Purpose-Driven Innovation?

HealthPad

Directory:

Medical Technology

Tags:

Artificial Intelligence

commentary

Machine Learning

Medtech

Effective MedTech leadership in the next decade requires adept navigation of companies through evolving markets, technological advancements, and simultaneous management of established legacy businesses
Historically, MedTech leaders have been drawn from a limited pool, potentially slowing effective adaptation to new technologies, and markets
This has allowed tech giants to disrupt the sector, emphasising a shift from the development of physical devices to integrated healthcare solutions
The 4th industrial revolution (Industry 4.0) is crucial in facilitating the transformation, breaking down traditional boundaries between medical devices, pharmaceuticals, software, and patient data
Executives with experience in service-based sectors adjacent to MedTech may be better equipped to lead, leveraging their tech-centric background to capitalise on digital technologies and big data strategies for successful adaptation and thriving in the evolving healthcare ecosystem

Is MedTech Entering a New Era of Leadership and Purpose-Driven Innovation?

MedTech leadership is at a crossroads, demanding a strategic overhaul to tackle unprecedented sector changes anticipated over the next decade. Navigating this evolving landscape requires reconciling traditional manufacturing expertise and cutting-edge digital capabilities. A forward-thinking CEO with digital acumen is pivotal for innovation, yet the complexities of manufacturing and stringent regulatory frameworks remain crucial. In response, it seems reasonable to suggest that a collaborative leadership approach would be optimal, pairing a visionary CEO with digital expertise alongside a seasoned COO well-versed in manufacturing and regulatory compliance. This, would not only alleviate the burden on a single leader but also combine the strengths of both domains, fostering a more resilient leadership model. By strategically aligning these skill sets, MedTech companies would be better positioned to adeptly bridge the gap between tradition and digital evolution amid the complexities of an increasingly competitive market.

Historically, MedTech leadership, drawn from a limited pool of individuals, may fall short in ensuring commercial success in the coming decade. The sector's reluctance to swiftly embrace emerging technologies has created an opening for tech giants to disrupt it, mirroring the upheavals witnessed in financial markets. To thrive, MedTech companies must shift from developing physical devices to strategically promoting integrated healthcare solutions and services. The 4^th Industrial Revolution, (Industry 4.0) plays a pivotal role in this evolution, breaking down traditional boundaries between medical devices, pharmaceuticals, software, and patient data. It reshapes connections among the physical, biological, and digital realms within the healthcare sector, emphasising advanced data and digitalisation strategies.

In this paradigm shift, traditional MedTech executives may find themselves ill-equipped to lead effectively. Executives from adjacent service-based sectors, with a tech-centric background, seem better positioned to spearhead this transformation. Leveraging their expertise, these leaders can adeptly capitalise on digital technologies and utilise big data strategies to navigate and adapt business models. Strategic leadership from executives with a tech-centric background is essential for MedTech companies to survive and thrive in the future.

In this Commentary

This Commentary has two parts. Part 1: The MedTech Market describes opportunities and challenges within the evolving dynamic global market. Part 2: Navigating MedTech’s Evolutionary Challenges, examines the limitations of current MedTech leadership, suggesting a shift towards diverse skills, backgrounds, and perspectives. Future MedTech leaders need expertise in digital technologies, data analytics, and innovative business models, coupled with an understanding of global markets and a compelling sense of purpose to engage and inspire Generation Zs. Takeaways raise the likelihood that existing MedTech executives may be ill-equipped for upcoming industry transformations, highlighting the potential of leaders from service-based sectors with proven strategic agility and innovation.

Part 1
The MedTech Market

Currently, MedTech is undergoing a transformation, and shedding its traditional conservative image. The industry's growth is driven by various factors, such as the aging global population, an uptick in chronic diseases, and an increasing trust in medical devices among clinicians and consumers, which has fostered stronger collaborations between MedTech and pharmaceutical companies. Although the US and the EU continue to be significant contributors to MedTech markets, they face hurdles, including increasingly stringent regulations, shifts in reimbursement policies, and elevated costs linked to advanced medical technologies.

About two decades ago, foreseeing constraints, some large MedTechs like Johnson & Johnson (J&J), Abbott, and Medtronic, strategically established manufacturing and research and development (R&D) centres in emerging markets such as Brazil, China, and India. Back then, these markets were undergoing substantial growth, fuelled by burgeoning middle-class populations with an increasing demand for improved healthcare services. This situation not only presented strategic opportunities for continuous expansion but also served as a buffer against the escalating difficulties experienced by MedTechs in the more mature Western markets.

Despite facing challenges, the global MedTech market continues to be a promising arena for growth and innovation, extending its reach across diverse sectors and geographies. Projections indicate that its global revenues will reach ~US$610bn in 2024, with an anticipated compound annual growth rate (CAGR) of ~5.2%. This trajectory points towards a substantial market volume of ~US$748bn by 2028. The US stands as the primary revenue contributor, expected to reach ~US$216bn in 2024. Historically, MedTech business models have predominantly targeted affluent markets in the US, Western Europe, and Japan, comprising only ~13% of the world's population but holding a significant market share. This historical skew allowed MedTech leaders to focus their marketing efforts on healthcare providers in prosperous developed regions, benefitting from favourable fee for service reimbursement policies. Notwithstanding, recent years have witnessed a tightening of the wealthy Western markets.

In the coming decade, MedTech sectors in emerging regions are set to experience significant growth. For example, in 2024 China's MedTech revenues are anticipated to realise ~US$46bn, with a projected CAGR to 2028 of ~7.5%. This growth trajectory is expected to culminate in a market volume of ~US$61bn in the near term. In the face of dynamic shifts, MedTech leaders are confronted with the challenge of recalibrating their strategies to ensure sustained success amid challenging global politico-economic conditions and the use of more demanding outcome-based healthcare reimbursement models in traditional wealthy Western markets.

You might also like:

Healthcare 2040

Following a peak in late 2021, MedTech stocks faced a setback around mid-2022, losing a significant portion of the gains accumulated during the Covid-19 pandemic. By July 2023, growth had slowed, with MedTech valuations showing only a modest increase of ~22% compared to January 2020. During this period, trading multiples experienced a decline, dropping from a peak of ~16x in September 2021 to ~7x by mid-2023, falling below the industry's 10-year average of ~8x.

Although there have been some recent improvements, the 2023 EY, Pulse of the MedTech Industry Report raised concerns about challenges ahead for the sector. In the post-Covid landscape, the industry is grappling with significant hurdles, including a notable decline in public valuations and ~30% decrease in financing. These challenges manifest in various aspects, such as a downturn in special-purpose acquisition company (SPAC) deals, a substantial decrease in the total value of initial public offerings (IPOs), and a slump of ~21% in venture capital (VC) funding. Compounding these issues is a decline of ~44% in merger and acquisition (M&A) activity.

Traditionally, M&A has played a crucial role for MedTechs, contributing to scale, operational leverage, financial performance, product portfolio diversification, improved therapeutic solutions, and international expansion - all while maintaining core manufacturing structures and strategies. Moreover, post-Covid, revenue growth has experienced a significant dip, dropping from ~16% in 2021 to ~3.5% in 2022, and remaining flat in 2023. The anticipated future growth of ~5% may encounter challenges due to a potential scarcity of new disruptive product offerings. These challenges have implications for equity investment, which hit a seven-year low in 2023, declining by ~27% to ~US$14bn. Notably this impacts smaller, innovation-driven firms.

A positive recent trend is the rapid growth of digital health with expected global revenues set to reach ~US$194bn by 2024, with a projected CAGR of ~9% from 2024 to 2028, which would deliver a market volume of ~US$275bn by 2028. China leads in global revenue generation for digital health, reaching ~US$53bn in 2024. However, many large diversified MedTechs with legacy products in slow-growing markets have yet to capitalise on this trend.

MedTech stands at a critical juncture, navigating challenges that necessitate a strategic overhaul for sustained success. The decline in key financial indicators and the sluggish pace of innovation pose significant threats, obliging leaders to embrace transformative strategies and capitalise on emerging trends, particularly in digital health, to secure a resilient future.

Part 2
Navigating MedTech’s Evolutionary Challenges

Changes in the MedTech landscape introduce difficulties for executives striving to stay abreast of technological advances and transformative shifts, particularly in emerging economies. Compounding these obstacles is the prevalence of middle-aged men in leadership roles, perpetuating traditional management styles that may impede the necessary adaptations required for growth.

You might also like:

Redefining Leadership In The Evolving Landscape Of MedTech

Despite women constituting >50% of the MedTech workforce and significantly influencing healthcare decisions, they are underrepresented in executive positions. Addressing these disparities is not just a moral obligation but a strategic imperative to unlock the full potential by embracing diverse perspectives and talents. The historical contributions of women in healthcare underscores the urgency of closing the gender gap in MedTech leadership.

Further complicating matters is the median age of C-suite executives; ~56. This demographic nearing retirement, suggests that many company leaders embarked on their professional journeys before the pervasive influence of the Internet, email, and the rise of social media platforms, creating a technological generation gap. The sector's historical reliance on affluent markets in the US and Europe, coupled with fee-for-service healthcare policies, poses challenges in adapting to emerging markets and reimbursement policies centred on patient outcomes.

The integration of artificial intelligence (AI) and machine learning (ML) into medical devices adds another layer of complexity, necessitating a paradigm shift. However, this transformation proves challenging for traditional leaders, given that these impactful changes unfolded during the mature phases of their careers. Notably, out of ~691 FDA-approved algorithms functioning as medical devices, ~35% received clearance in 2022 and 2023. Despite the urgent need for adaptation, persistent leadership obstacles hinder progress, particularly in understanding and aligning with the fluidity of rapidly evolving technologies in new markets.

MedTech leaders face challenges in understanding the dynamics of emerging markets, especially in economically vibrant regions like Brazil, India, China, and sizable African nations. These areas experience economic development and a growing middle class, leading to increased demand for advanced healthcare. The global acumen gap is further intensified by a lack of first-hand experience among these professionals in these regions, presenting a hurdle to effective guidance. Consequently, many MedTech executives seem to struggle with delivering impactful direction, given the disconnect with transformative trends in emerging markets and advancing technologies. Addressing these perspective and knowledge gaps requires more than incremental adjustments; it calls for a shift in mindset and a recalibration.

Significant changes in MedTech call for a departure from traditional top-down directives towards an empowering leadership style. The sector now demands a new breed of leaders - tech savvy individuals with global experience capable of understanding and connecting with the needs and aspirations of Generation Z employees. This demographic shift in the workforce requires leaders who not only comprehend evolving technologies but also align with the values and expectations of today's highly skilled, young professionals. Beyond the pursuit of shareholder value, this demographic craves purpose-driven leadership and seeks companies with a clear sense of mission and societal impact. In this context, MedTech companies face a stark choice: adapt to lead with purpose or risk being left behind.

Takeaways

The future leadership of MedTech companies stands at a critical juncture as it is potentially faced with unprecedented changes over the next decade. While the necessity of a forward-looking CEO with digital acumen is essential for strategic innovation, the persisting challenges of manufacturing and regulatory frameworks highlight the need for a more collaborative leadership approach. To address this, we have proposed a strategic collaboration between a visionary CEO equipped with digital expertise and a seasoned COO skilled in manufacturing and compliance. It seems reasonable to assume that this would not only ease the burden on a single individual but also harness the strengths of both, fostering a more resilient leadership approach. Further, it recognises that navigating change demands a balance between embracing digital evolution and maintaining a strong foundation in traditional manufacturing and regulatory compliance. Future MedTech leaders must be able to bridge knowledge and perspective gaps, align with emerging technologies, and connect with the aspirations of the evolving workforce. The shift towards a more empowering leadership style, coupled with an understanding of Industry 4.0 principles and the dynamics of emerging markets, is essential for sustained success in a rapidly evolving market.

The urgency for MedTech leaders to adopt a forward-thinking, adaptable, and purpose-driven approach cannot be overstressed. The industry's capacity to allure and retain talent, foster innovation, and make substantial contributions to global healthcare pivots on a commitment to purposeful leadership and the incorporation of transformative strategies. In this demanding journey, the judicious collaboration between a forward-looking CEO and a traditional COO emerges as a strategic imperative, ensuring a comprehensive and resilient leadership model that can thrive in the next decade.

view in full page

10 months, 2 weeks ago

12797
0
Facebook

Twitter

Google+

LinkedIn

Report

Signs of endometriosis

Dr. Amir Marashi, MD

Directory:

Tags:

endometriosis specialist nyc

endometriosis treatment

hymen removal surgery

labiaplasty nyc

pelvic floor reconstruction

pelvic sonogram

pelvic ultrasound

septate hymen surgery

Finding an endometriosis specialist is crucial to getting proper treatment for the disease. Important to see a well qualified and well-trained minimally invasive GYN surgical specialist who is board-certified and fellowship-trained. Dr. Marashi is an internationally recognized board-certified expert and renowned specialist in minimally invasive laparoscopic endometriosis surgery.

What Is Endometriosis?
EndometriosisEndometriosis is a disease that affects women, usually between the age of 25 and 40. This disorder is one of the main causes of infertility among women.

It never appears before puberty and always ends at the time of menopause due to a lack of ovarian hormones. The incidence of endometriosis is higher in infertile women, between 25-40 %, while in the general population, endometriosis has an incidence of 3 – 10 %.

Endometriosis is characterized by the growth of uterine tissue outside of the endometrium. This uterine tissue grows inside of the myometrium or even outside of the uterus.

Internal Endometriosis – When the uterine tissue grows inside of the myometrium, it is called Adenomyosis or Internal Endometriosis.

External Endometriosis – When the uterine tissue grows outside of the uterus, it is called External Endometriosis. The uterine tissue can be found almost in every part and organ of the body, but it is more common in the ovaries, peritoneum, rectum, intestine, vagina, vulva, bladder, liver, etc.

Until today the real cause of pelvic endometriosis is not known. However, there are several theories that try to explain it. The most acceptable theories include:

Metaplasic theory
Implantation theory
Metastatic theory
Surgical scar implantation
Immune system disorder

Brooklyn GYN Place
142 Joralemon Street, #4CF,
Brooklyn, NY 11201
(718) 624-0604

Web Address:
https://www.brooklyngynplace.com/

Our location on the map: https://goo.gl/maps/TdxdKLtq6PuS65ck9

Nearby Locations:
Downtown Brooklyn | Fort Greene | Boerum Hill | Cobble Hill | Columbia Street Waterfront District
11201| 11205 | 11217 | 11238 | 11231

Working Hours:
Monday - Friday: 9am - 5:30pm
Saturday: 9am - 11:30am
Sunday: Closed

Payment: cash, check, credit cards.

view in full page

10 months, 2 weeks ago

8548
0
Facebook

Twitter

Google+

LinkedIn

Report

Brooklyn GYN Place offers a discount

Dr. Amir Marashi, MD

Directory:

Tags:

Brooklyn GYN Place offers a discount

Brooklyn GYN Place has over 20 years of experience and offers the full range of OB/GYN procedures. All procedures and exams are performed in a safe and comfortable setting, our fully licensed facility. We serve Brooklyn Heights, Red Hook, Park Slope and Bedford-Stuyvesant areas. We are currently running a limited time event for all new patients. If you’re a first-time patient, make an appointment today and receive 5–10% off.

Brooklyn GYN Place
142 Joralemon Street, #4CF,
Brooklyn, NY 11201
(718) 624–0604

Web-address: https://www.brooklyngynplace.com/

Location on the map: https://goo.gl/maps/TdxdKLtq6PuS65ck9